Dr. Alain Catalin Mita, MD

Dr. Mita practices at Hoag Hospital Newport Beach in Newport Beach, California, part of Hoag Memorial Hospital Presbyterian.

Dr. Mita's NPI, 1285602565, was assigned on March 10, 2006. Dr. Mita graduated from Carol Davila University of Medicine and Pharmacy in 1992. Dr. Mita holds Texas license M3028.

Dr. Mita's primary practice is Hoag Hospital Newport Beach, at One Hoag Drive, Newport Beach, CA 92663 in Orange County. The practice phone is (949) 764-4624. Dr. Mita also practices at Hoag Hospital Newport Beach, 1 Hoag Dr, Newport Beach, CA 92663.

Dr. Mita's primary practice is Hoag Hospital Newport Beach in Newport Beach, California, part of Hoag Memorial Hospital Presbyterian. Dr. Mita is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Hoag Clinic. Dmand AI also links Dr. Mita to 1 more home health agency, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mita practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Mita's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Mita's licenses on file in 3 states: Texas, California and Alabama.

Dmand AI lists breast cancer and lung cancer among the conditions Dr. Mita treats.

CMS data shows 476 Medicare services from Dr. Mita across 4 procedure codes in 2024, for 139 Medicare patients. Medicare paid $48,753 for them.

CMS counts 139 Medicare patients who saw Dr. Mita in 2024. The largest group is 65 to 74, with 76 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mita's median patient age at 75, with 51% women.

In 2024, Dr. Mita wrote 399 Medicare Part D claims for 77 patients. 78% of them were for generic drugs. CMS names the drug for 184 of them, across 9 drugs with 11 or more claims each, at $498,822 in total drug cost. In 2023, CMS named 162 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Mita for performance year 2024, reported as part of a group. Dr. Mita accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mita as offering telehealth.

Dmand AI links 108 papers to Dr. Mita, published from 2003 to 2024. 2014 was the busiest year, with 9. The most frequent topics are Antineoplastic Agents, Maximum Tolerated Dose and Antineoplastic Combined Chemotherapy Protocols. Dr. Mita has published most often in Clin Cancer Res. Dr. Mita's most frequent co-authors are Monica Mirela Mita, MD, John Sarantopoulos, MD and Eric Keith Rowinsky.

Dmand AI links Dr. Mita to 7 clinical trials, 3 of them phase 1/2 studies. Conditions studied include Esthesioneuroblastoma, Olfactory, Fallopian Tube Diseases and Neoplasm Metastasis. ImmunoGen, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Mita that name 2 trials.

CMS Open Payments shows 63 general payments to Dr. Mita from 22 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 62% of the total. Genentech, Inc. paid the most, $24,423. It also lists 4 research payments totaling $1,485 from 2016 to 2017, naming 2 clinical trials.

Dr. Mita graduated from Carol Davila University of Medicine and Pharmacy in 1992. Dr. Mita is a member of ASCO.

Dr. Mita is in network with 10 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.